capecitabine has been researched along with Minimal Disease, Residual in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 7 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albacker, LA; Badve, S; Bales, CL; Ballinger, TJ; Blaya, M; Cantor, E; Chen, YH; Chitambar, C; Cooper, ME; Daily, K; Falkson, C; Gallagher, C; Graham, R; Gregg, J; Hancock, BA; Helft, P; Isaacs, C; Jiang, G; Kassem, N; Lynce, FC; Mahtani, R; Miller, KD; Nanda, R; O'Neil, B; Paplomata, E; Pavlick, DC; Radovich, M; Schneider, BP; Shen, F; Solzak, JP; Storniolo, AMV; Thompson, MA; Walling, R | 1 |
| Arıkan, R; Atcı, MM; Ay, S; Ayhan, M; Bayram, E; Dülgar, Ö; Gümüş, M; Öven, BB; Özcan, E; Ozyukseler, DT; Selvi, O; Yasin, Aİ | 1 |
| Dasari, A; Deming, D; George, TJ; Kopetz, S; Lieu, CH; Lin, Y; Lucas, PC; Sahin, IH; Yothers, G | 1 |
| Abramson, VG; Ayala-Peacock, DN; Chakravarthy, AB; Mayer, IA; Rexer, BN; Sherry, AD | 1 |
| Bosch, LJW; Coupé, VMH; Elias, S; Fijneman, RJA; Koopman, M; Laclé, MM; Meijer, GA; Phallen, J; Rubio Alarcón, C; Sausen, M; Schraa, SJ; Simmons, J; van den Broek, D; van der Kruijssen, DEW; van Grevenstein, WMU; van Rooijen, KL; Velculescu, VE; Verkooijen, HM; Vink, GR | 1 |
| An, X; Bi, XW; Cai, L; Cao, Y; Chen, QJ; Guo, Y; He, ZY; Hong, RX; Hua, X; Huang, H; Huang, JJ; Huang, ZZ; Jiang, KK; Ke, YL; Li, JB; Lin, HX; Lin, Y; Liu, XM; Pang, DM; Peng, RJ; Shi, W; Shi, YX; Song, CG; Su, YH; Tang, J; Wang, SS; Wang, X; Wang, XM; Wang, XY; Xia, W; Xu, F; Xue, C; Yuan, ZY; Zeng, J; Zhang, AQ; Zhang, LH; Zhao, L; Zhong, YY | 1 |
| Bigness, A; Felder, S; Frakes, J; Hoffe, S; Imanirad, I; Laskowitz, D; Sahin, IH; Xie, H | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Carey, LA | 1 |
| DeMichele, A; Patel, SA | 1 |
| Anthoney, A; Germetaki, T; Kamposioras, K; Kordatou, Z; Mansoor, W; Nasralla, M; Owen-Holt, V; Papaxoinis, G; Stamatopoulou, S; Weaver, JMJ | 1 |
| Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B | 1 |
| Cherkassky, L; Jarnagin, W | 1 |
| Bosch, SL; Cats, A; Dewit, LG; Marijnen, CA; Nagtegaal, ID; Swellengrebel, HA; Verwaal, VJ; Vincent, AD | 1 |
| Egami, T; Ienaga, J; Ikubo, A; Inoue, S; Ishikawa, M; Konomi, H; Manabe, T; Nagayoshi, K; Nakamura, M; Tanaka, M; Ueki, T; Yamanaka, N | 1 |
| Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP | 1 |
| Choe, AR; Choi, JE; Lee, KE; Nam, EM; Park, H; Yoon, SE | 1 |
| Ihemelandu, C; Sugarbaker, PH | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, MK; Kim, SB; Kim, YH; Lee, GH; Park, SI; Ryu, JS; Shin, JH; Song, HJ; Song, HY | 1 |
| Bakers, FC; Barbaro, B; Beets, GL; Beets-Tan, RG; Haustermans, K; Lambrecht, M; Lambregts, DM; Maas, M; Valentini, V; Vandecaveye, V | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Dalton, RS; Daniels, IR; Gee, AS; Harries, S; Osborne, ME; Thomas, R; Velineni, R | 1 |
| Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Deshpande, V; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Warshaw, AL; Willett, CG; Zhu, AX | 1 |
| Arias, F; Arrazubi, V; Balén, E; Gómez, M; Guerrero, D; Suárez, J; Vera, R; Viúdez, A | 1 |
2 review(s) available for capecitabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Triple Negative Breast Neoplasms | 2017 |
Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase III as Topic; Gallbladder Neoplasms; Humans; Incidental Findings; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prognosis; Randomized Controlled Trials as Topic; Risk; Risk Assessment | 2019 |
7 trial(s) available for capecitabine and Minimal Disease, Residual
| Article | Year |
|---|---|
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Circulating Tumor DNA; Clinical Decision-Making; Disease-Free Survival; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Patient Selection; Precision Medicine; Predictive Value of Tests; Time Factors; Triple Negative Breast Neoplasms | 2022 |
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Circulating Tumor DNA; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2022 |
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Circulating Tumor DNA; Colectomy; Colonic Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liquid Biopsy; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Netherlands; Oxaliplatin; Patient Acceptance of Health Care; Practice Guidelines as Topic; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinica
Topics: Adult; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Observation; Triple Negative Breast Neoplasms | 2021 |
A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Oxaloacetates; Pilot Projects; Prospective Studies; Rectal Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate | 2016 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
16 other study(ies) available for capecitabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Triple Negative Breast Neoplasms | 2022 |
Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity.
Topics: Adult; Breast; Breast Neoplasms; Capecitabine; Case-Control Studies; Chemoradiotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Chemoradiotherapy; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Organ Sparing Treatments; Organoplatinum Compounds; Proctectomy; Rectal Neoplasms | 2021 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
De-escalating and escalating systemic therapy in triple negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm, Residual; Platinum Compounds; Taxoids; Triple Negative Breast Neoplasms; Tumor Burden | 2017 |
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Perioperative Period; Propensity Score; Retrospective Studies; Survival Rate | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fluorouracil; Humans; Inguinal Canal; Leucovorin; Liver; Liver Neoplasms; Lymphatic Metastasis; Male; Microsatellite Instability; Neoplasm, Residual; Nivolumab; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Treatment Outcome | 2019 |
Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Preoperative Care; Proportional Hazards Models; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Remission Induction; Retrospective Studies; Survival Rate | 2014 |
Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Capecitabine; Cisplatin; Endodermal Sinus Tumor; Etoposide; Humans; Male; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Tomography, X-Ray Computed | 2017 |
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cytoreduction Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Mucin-1; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2017 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Analysis | 2009 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Fluorouracil; Follow-Up Studies; Gamma Rays; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Rectal Neoplasms; Retrospective Studies; Time Factors | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Sex Factors; Tumor Burden | 2012 |
Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Topics: 3' Untranslated Regions; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Polymorphism, Genetic; Rectal Neoplasms; Sequence Deletion; Thymidylate Synthase | 2013 |